4-bromo-2,5-dimethylbenzonitrile | 292037-85-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-bromo-2,5-dimethylbenzonitrile
• CAS: 292037-85-5
• 化学式: C₉H₈BrN
• 分子量: 210.073
• InChiKey: HZMQTNIFPKVBFC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  23.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  4-bromo-2,5-dimethylbenzonitrile 在 硫酸 作用下， 生成 4-bromo-2,5-dimethyl-benzoic acid amide
  参考文献：
  名称：

  The Xylic Acids Obtained in the Oxidation of 5-Bromo and 5-Nitropseudocumene

  摘要：

  DOI：

  10.1021/ja01312a062
• 作为产物：
  描述：

  4-溴-2,5-二甲基苯胺 生成 4-bromo-2,5-dimethylbenzonitrile
  参考文献：
  名称：

  The Xylic Acids Obtained in the Oxidation of 5-Bromo and 5-Nitropseudocumene

  摘要：

  DOI：

  10.1021/ja01312a062

文献信息

• [EN] PYRAZOLE DERIVATIVES AS S1P1 AGONISTS<br/>[FR] DÉRIVÉS DU PYRAZOLE EN TANT QU'AGONISTES S1P1
  申请人：ALMIRALL SA

  公开号：WO2011144338A1

  公开（公告）日：2011-11-24

  The present invention relates to a compound of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by sphingosine-1-phosphate receptors (S1P1) agonists.

  本发明涉及式(I)的化合物，制备此类化合物的方法以及它们在治疗可通过鞘氨醇-1-磷酸受体（S1P1）激动剂改善的病理状况或疾病中的用途。
• New pyrazole derivatives
  申请人：Almirall, S.A.

  公开号：EP2390252A1

  公开（公告）日：2011-11-30

  The present invention relates to a compound of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by sphingosine-1-phosphate receptors (S1P1) agonists.

  本发明涉及式(I)的化合物，其制备过程，以及它们在治疗可通过sphingosine-1-phosphate受体（S1P1）激动剂改善的病理状况或疾病中的用途。
• Iron(II)‐Catalyzed Direct Cyanation of Arenes with Aryl(cyano)iodonium Triflates
  作者：Zhibin Shu、Wenzhi Ji、Xi Wang、Yujing Zhou、Yan Zhang、Jianbo Wang

  DOI：10.1002/anie.201309791

  日期：2014.2.17

  A direct oxidative cyanation of arenes under FeII catalysis with 3,5‐di(trifluoromethyl)phenyl(cyano)iodonium triflate (DFCT) as the cyanating agent has been developed. The reaction is applicable to wide range of aromatic substrates, including polycyclic structures and heteroaromatic compounds.

  已经开发了在Fe II催化下使用3,5-二（三氟甲基）苯基（氰基）碘化三氟甲磺酸盐（DFCT）作为氰化剂的芳烃直接氧化氰化反应。该反应适用于多种芳族底物，包括多环结构和杂芳族化合物。
• [EN] INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL<br/>[FR] INHIBITEURS DU CANAL POTASSIQUE MÉDULLAIRE EXTERNE RÉNAL
  申请人：MERCK SHARP & DOHME

  公开号：WO2015105736A1

  公开（公告）日：2015-07-16

  The present invention provides compounds of Formula (I) and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

  本发明提供了式（I）的化合物及其药学上可接受的盐，这些化合物是ROMK（Kir1.1）通道的抑制剂。这些化合物可用作利尿剂和/或钠利尿剂，并用于治疗和预防包括高血压、心力衰竭和慢性肾病在内的心血管疾病以及与过多盐分和水分潴留有关的疾病。
• INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20170037037A1

  公开（公告）日：2017-02-09

  The present invention provides compounds of Formula (I) and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

  本发明提供了式（I）的化合物及其药学上可接受的盐，这些化合物是ROMK（Kir1.1）通道的抑制剂。这些化合物可用作利尿剂和/或钠利尿剂，并用于治疗和预防包括高血压、心力衰竭和慢性肾病在内的心血管疾病以及与过多盐分和水分潴留有关的疾病。